Jag Capital Management LLC raised its holdings in Iqvia Holdings Inc (NYSE:IQV) by 44.7% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 111,525 shares of the medical research company’s stock after buying an additional 34,434 shares during the period. Iqvia makes up approximately 2.6% of Jag Capital Management LLC’s portfolio, making the stock its 17th largest position. Jag Capital Management LLC’s holdings in Iqvia were worth $16,043,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. BlackRock Inc. lifted its position in shares of Iqvia by 3.2% during the 4th quarter. BlackRock Inc. now owns 10,977,184 shares of the medical research company’s stock worth $1,275,219,000 after purchasing an additional 342,256 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its position in shares of Iqvia by 44,777.1% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 7,140,389 shares of the medical research company’s stock worth $61,000 after purchasing an additional 7,124,478 shares during the last quarter. FMR LLC lifted its position in shares of Iqvia by 41.1% during the 4th quarter. FMR LLC now owns 4,217,991 shares of the medical research company’s stock worth $490,004,000 after purchasing an additional 1,228,148 shares during the last quarter. AQR Capital Management LLC lifted its position in shares of Iqvia by 10.2% during the 3rd quarter. AQR Capital Management LLC now owns 2,996,536 shares of the medical research company’s stock worth $388,771,000 after purchasing an additional 277,477 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Iqvia by 8.4% during the 4th quarter. Geode Capital Management LLC now owns 2,130,570 shares of the medical research company’s stock worth $247,087,000 after purchasing an additional 164,811 shares during the last quarter. 91.00% of the stock is owned by institutional investors.
Several equities research analysts have recently issued reports on IQV shares. Goldman Sachs Group raised shares of Iqvia from a “buy” rating to a “conviction-buy” rating in a research report on Friday, January 11th. Jefferies Financial Group raised shares of Iqvia from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $136.00 to $150.00 in a research report on Friday, January 18th. Piper Jaffray Companies lifted their price objective on shares of Iqvia to $148.00 and gave the stock a “neutral” rating in a research report on Friday, February 15th. UBS Group set a $170.00 price objective on shares of Iqvia and gave the stock a “buy” rating in a research report on Friday, February 15th. Finally, Barclays reaffirmed a “buy” rating and set a $155.00 price objective on shares of Iqvia in a research report on Friday, February 15th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $146.88.
In other news, Director Ronald A. Rittenmeyer sold 3,840 shares of Iqvia stock in a transaction dated Tuesday, February 5th. The shares were sold at an average price of $130.00, for a total value of $499,200.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Michael J. Evanisko sold 1,193 shares of Iqvia stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $144.95, for a total transaction of $172,925.35. The disclosure for this sale can be found here. In the last ninety days, insiders sold 4,172,538 shares of company stock worth $587,465,163. Insiders own 6.00% of the company’s stock.
NYSE IQV traded down $1.44 during trading on Monday, reaching $141.08. The company’s stock had a trading volume of 950,829 shares, compared to its average volume of 1,264,416. The firm has a market cap of $28.03 billion, a PE ratio of 27.55, a P/E/G ratio of 1.74 and a beta of 0.85. The company has a debt-to-equity ratio of 1.57, a quick ratio of 1.10 and a current ratio of 1.10. Iqvia Holdings Inc has a twelve month low of $91.57 and a twelve month high of $146.10.
Iqvia (NYSE:IQV) last issued its earnings results on Thursday, February 14th. The medical research company reported $1.50 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.47 by $0.03. The business had revenue of $2.69 billion for the quarter, compared to the consensus estimate of $2.62 billion. Iqvia had a net margin of 2.49% and a return on equity of 14.25%. The business’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.40 earnings per share. Research analysts predict that Iqvia Holdings Inc will post 5.87 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This news story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2019/04/15/jag-capital-management-llc-acquires-34434-shares-of-iqvia-holdings-inc-iqv.html.
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
See Also: How are Outstanding Shares Different from Authorized Shares?
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.